Organogenesis
ORGO Healthcare Drug Manufacturers Specialty & Generic
Organogenesis' revenue for fiscal 2025 (year ended December 2025) was $564.2 million, up 17.0% from fiscal 2024. In the quarter to June 2026, revenue fell 56.7%, EPS fell 670.0%, free cash flow grew 10.3% and total debt rose 10,940.8%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow ORGO
Organogenesis (ORGO) Piotroski F-score
Organogenesis's Piotroski F-score for fiscal 2025 is 4 out of 9: 4 of nine tests of profitability, leverage and efficiency passed, down from 6 in fiscal 2024.
Piotroski F-score, annual
Embed this chart
Annual newest first
| Period | Piotroski F-score | Change (points) |
|---|---|---|
| FY2025 | 4 | (2.00) |
| FY2024 | 6 | 2.00 |
| FY2023 | 4 | (2.00) |
| FY2022 | 6 | 0.00 |
| FY2021 | 6 | 0.00 |
| FY2020 | 6 | 1.00 |
| FY2019 | 5 | — |
How fiscal 2025’s score is made up
| Test | This year | Year before | Result | Points |
|---|---|---|---|---|
| Positive return on assets | 3.65% | (0.20%) | Pass | 1 |
| Positive operating cash flow | (10.31m) | 14.21m | Fail | 0 |
| Rising return on assets | 3.65% | (0.20%) | Pass | 1 |
| Cash flow above net income | (30.33m) | 15.15m | Fail | 0 |
| Falling long-term leverage | 0.02 | 0.00 | Fail | 0 |
| Rising current ratio | 3.62 | 3.69 | Fail | 0 |
| No new shares issued | 126,738,100 | 131,673,300 | Pass | 1 |
| Rising gross margin | 75.62% | 75.99% | Fail | 0 |
| Rising asset turnover | 1.03 | 1.01 | Pass | 1 |
| Piotroski F-score | Mixed | 4 | ||
How the Piotroski F-score works
One point for each of nine tests, this fiscal year against the one before: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, a rising current ratio, no new shares issued, a rising gross margin and rising asset turnover. The ratios are the ones on this site, so each can be checked.
Joseph Piotroski (2000) called 8–9 high and 0–1 low; reading it in three bands is the common convention:
| 7–9 | Strong — most fundamentals improved |
|---|---|
| 4–6 | Mixed |
| 0–3 | Weak — most fundamentals deteriorated |
Where this differs from the paper: return on assets is on average rather than beginning-of-year assets, and weighted basic shares stand in for shares issued. The score is shown only when all nine tests can be worked out, which takes three fiscal years; banks and insurers, which report no current assets or gross profit, have none.
Piotroski F-score against peers
| Company | Piotroski F-score |
|---|---|
| AKBA Akebia Therapeutics, Inc. compare | 7 |
| CPIX Cumberland Pharmaceuticals Inc. compare | 6 |
| OGI Organigram Global Inc. compare | 5 |
| ORGO Organogenesis | 4 |
| DERM Journey Medical Corporation compare | 4 |
| BGM BGM Group Ltd. compare | 3 |
| CLVR Clever Leaves Holdings Inc. compare | 3 |
| PROCF Sofgen Pharma S.A compare | 3 |
| CRDL Cardiol Therapeutics Inc. compare | — |
What Piotroski F-score is
The Piotroski F-Score tells an investor how many signs of improving profitability, funding and efficiency a company shows against a year earlier.
One point for each of nine tests against a year earlier: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, rising current ratio, no new shares issued, rising gross margin, and rising asset turnover